EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study

Ali Yari iD, Carl-Emil Lim iD, Emil Hagström iD, Pia Lundman iD, Jessica Schubert iD, Tomas Jernberg iD, Peter Ueda iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2026

DOI: 10.1093/ehjcvp/pvaf079 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2026. Verfasst von Ali Yari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 182 88 Stockholm, Sweden. Hauptthemen laut MEDLINE: Secondary Prevention, Myocardial Infarction, Cardiovascular Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To analyse utilization and discontinuation of secondary preventive medications after acute myocardial infarction (MI). Methods and results In separate analyses for each drug [statins, beta-blockers, aspirin, and renin-angiotensin-aldosterone system (RAAS) inhibitors], patients with a first-time MI (2006–2021) registered in the nationwide Swedish MI register SWEDEHEART, surviving >30 days, and discharged with a new prescription of the drug were included. Based on filled prescriptions, treatment initiation, discontinuation (defined as ≥90-day period of non-treatment after the end of previous prescriptions), reinitiation (restarting treatment after discontinuation), and the proportion of patients with ongoing treatment at various time points after the MI were assessed. The analyses included 159 155 patients: 122 288 patients discharged with a statin, 79 968 with a RAAS inhibitor, 105 095 with a beta-blocker, and 127 463 with aspirin: 95%–97% of the patients filled their first prescription for the drug. Treatment discontinuation ranged from 12% to 14% at 1 year, 27%–37% at 5 years, and 36%–51% at 12 years across drugs. Among those who discontinued treatment, the proportion who reinitiated treatment was 28%–46% at 1 year, 42%–62% at 5 years, and 47%–67% at 12 years after discontinuation across drugs. The proportion of patients who were alive with ongoing treatment (regardless of previous discontinuation/reinitiation episodes) was 91%–92% at 1 year, 79%–82% at 5 years, and 74%–79% at 12 years after the index MI.

Conclusion

Discontinuation of secondary preventive medications was common, but so was reinitiation. Thus, the proportion of patients with ongoing treatment was 91%–92% at 1 year and 74%–79% at 12 years after the MI. This study, which did not assess reasons for drug discontinuation, indicates that long-term utilization of secondary preventive medication after MI may not be as low as previously thought.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Secondary PreventionMyocardial InfarctionCardiovascular AgentsPractice Patterns, Physicians'HumansMaleFemaleSwedenAgedTime FactorsMiddle AgedRegistriesTreatment OutcomeRisk FactorsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsRecurrenceDrug UtilizationWithholding TreatmentHydroxymethylglutaryl-CoA Reductase InhibitorsAspirin

Stichwörter der Autor:innen

AdherenceDiscontinuationInitiationMyocardial infarctionPersistenceSecondary prevention

Substanzen

Cardiovascular AgentsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsAspirin

Autor:innen und Institutionen

  • Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 182 88 Stockholm, Sweden.
  • Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Department of Medical Sciences, Cardiology, Uppsala University, 751 85 Uppsala, Sweden.
  • Centre for Diabetes, Academic Specialist Centre, 113 65 Stockholm, Sweden.

ORCID-Profile: Ali Yari, Carl-Emil Lim, Emil Hagström, Pia Lundman, Jessica Schubert, Tomas Jernberg, Peter Ueda

Zitieren

APA

Yari, A., Lim, C. E., Hagström, E., Lundman, P., Schubert, J., Jernberg, T., & Ueda, P. (2026). Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvaf079

Vancouver

Yari A, Lim CE, Hagström E, Lundman P, Schubert J, Jernberg T, et al. Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. 2026. doi:10.1093/ehjcvp/pvaf079

BibTeX
@article{Yari2026,
  author = {Yari, Ali and Lim, Carl-Emil and Hagström, Emil and Lundman, Pia and Schubert, Jessica and Jernberg, Tomas and Ueda, Peter},
  title = {Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2026},
  doi = {10.1093/ehjcvp/pvaf079}
}
Kostenlos starten →